- Home
- QH vs GNPX Comparison
QH vs GNPX Comparison
Compare QH & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- GNPX
- Stock Information
- Founded
- QH 2012
- GNPX 2009
- Country
- QH China
- GNPX United States
- Employees
- QH 421
- GNPX N/A
- Industry
- QH Business Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- QH Consumer Discretionary
- GNPX Health Care
- Exchange
- QH Nasdaq
- GNPX Nasdaq
- Market Cap
- QH 6.6M
- GNPX 5.5M
- IPO Year
- QH 2020
- GNPX 2018
- Fundamental
- Price
- QH $6.70
- GNPX $0.27
- Analyst Decision
- QH
- GNPX
- Analyst Count
- QH 0
- GNPX 0
- Target Price
- QH N/A
- GNPX N/A
- AVG Volume (30 Days)
- QH 95.1K
- GNPX 24.1M
- Earning Date
- QH 08-28-2025
- GNPX 11-12-2025
- Dividend Yield
- QH N/A
- GNPX N/A
- EPS Growth
- QH N/A
- GNPX N/A
- EPS
- QH 0.80
- GNPX N/A
- Revenue
- QH $417,431,053.00
- GNPX N/A
- Revenue This Year
- QH N/A
- GNPX N/A
- Revenue Next Year
- QH N/A
- GNPX N/A
- P/E Ratio
- QH $8.29
- GNPX N/A
- Revenue Growth
- QH N/A
- GNPX N/A
- 52 Week Low
- QH $3.93
- GNPX $0.14
- 52 Week High
- QH $169.07
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- QH 26.97
- GNPX 62.31
- Support Level
- QH $6.01
- GNPX $0.20
- Resistance Level
- QH $7.07
- GNPX $0.32
- Average True Range (ATR)
- QH 0.60
- GNPX 0.05
- MACD
- QH 2.93
- GNPX 0.01
- Stochastic Oscillator
- QH 88.09
- GNPX 49.54
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.